Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.71+0.10 (+0.26%)
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Roivant Sciences cash
Cash and short-term investments held at the end of each period.
Roivant Sciences's cash was $3.84B at Jun 30, 2026. For fiscal 2025 it was $4.29B, down 12.2% from the year before. The highest annual figure on record is $6.49B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | $4.29B | -12.2% |
| FY2024 | Mar 31, 2025 | $4.89B | -24.8% |
| FY2023 | Mar 31, 2024 | $6.49B | +283.8% |
| FY2022 | Mar 31, 2023 | $1.69B | -18.4% |
| FY2021 | Mar 31, 2022 | $2.07B | -3.2% |
| FY2020 | Mar 31, 2021 | $2.14B | -5.6% |
| FY2019 | Mar 31, 2020 | $2.27B | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | $3.84B | -14.7% |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $4.29B | -12.2% |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | $4.53B | -12.0% |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | $4.39B | -18.6% |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | $4.50B | -20.7% |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | $4.89B | -24.8% |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | $5.15B | -22.9% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | $5.39B | +282.5% |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | $5.68B | +291.7% |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | $6.49B | +283.8% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $6.67B | +332.9% |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | $1.41B | -12.7% |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | $1.45B | -25.9% |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $1.69B | -18.4% |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | $1.54B | -30.8% |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | $1.61B | -35.7% |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | $1.96B | -2.6% |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | $2.07B | -3.2% |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | $2.23B | +3.4% |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | $2.51B | +5.0% |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | $2.01B | -13.2% |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | $2.14B | -5.6% |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | $2.15B | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | $2.39B | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | $2.31B | – |
| Q4 FY2019CQ1 2020 | Mar 31, 2020 | $2.27B | – |
See a number that looks wrong?